Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose blinatumomab for refractory autoimmune encephalitis and autoimmune cerebellitis
ChiCTR2600127018Phase 4Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of blinatumomab in Autoimmune Encephalitis (AE) and Autoimmune cerebellitis (AC), sponsored by Beijing Tiantan Hospital. Primary endpoints: Modified Rankin Scale (mRS), Clinical Assessment Scale for Autoimmune Encephalitis (CASE) and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
Autoimmune Encephalitis (AE)Autoimmune cerebellitis (AC)
Beyond the preview
Go deeper on ChiCTR2600127018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127018.